Advertisement
UK markets closed

  • FTSE 100

    8,440.64
    +59.29 (+0.71%)
     

  • FTSE 250

    20,654.93
    +123.63 (+0.60%)
     

  • AIM

    790.13
    +6.43 (+0.82%)
     

  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2515
    -0.0008 (-0.07%)
     

  • Bitcoin GBP

    48,910.26
    -644.51 (-1.30%)
     

  • CMC Crypto 200

    1,302.78
    -55.23 (-4.18%)
     

  • S&P 500

    5,213.28
    -0.80 (-0.02%)
     

  • DOW

    39,426.67
    +38.91 (+0.10%)
     

  • CRUDE OIL

    79.17
    -0.09 (-0.11%)
     

  • GOLD FUTURES

    2,370.70
    +30.40 (+1.30%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,770.23
    +83.63 (+0.45%)
     

  • CAC 40

    8,216.94
    +29.29 (+0.36%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

AstraZeneca pulls cancer drug application in Europe

Reuters - UK Focus

LONDON, Sept 21 (Reuters) - AstraZeneca (NYSE: AZN - news) has pulled an application seeking European approval to sell its experimental cancer drug cediranib in combination with chemotherapy to treat ovarian cancer because of late-stage questions raised by regulators reviewing the product.

However, the British company said on Wednesday that cediranib, a so-called VEGFR inhibitor, remained an important pipeline medicine and the decision did not affect its ongoing development in combination tests alongside other drugs. (Reporting by Ben Hirschler; editing by Jason Neely)